BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
01 Jun 2024
01 Jun 2024
Historique:
revised:
03
05
2024
received:
30
01
2024
accepted:
20
05
2024
medline:
1
6
2024
pubmed:
1
6
2024
entrez:
1
6
2024
Statut:
aheadofprint
Résumé
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are life-threatening hematopoietic malignancies characterized by clonal expansion of leukemic blasts in the bone marrow and peripheral blood. The epigenetic reader BRD4 and its downstream effector MYC have recently been identified as potential drug targets in human AML and ALL. We compared anti-leukemic efficacies of the small-molecule BET inhibitor JQ1 and the recently developed BRD4 degraders dBET1 and dBET6 in AML and ALL cells. JQ1, dBET1, and dBET6 were found to suppress growth and viability in all AML and ALL cell lines examined as well as in primary patient-derived AML and ALL cells, including CD34
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Austrian Science Fund (FWF)
ID : ERANET-PLL I 4156B
Organisme : Austrian Science Fund (FWF)
ID : EuroTCLym I 4154B
Organisme : Medical University of Vienna
Informations de copyright
© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
Références
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136‐1152.
Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146‐1162.
Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108(2):308‐320.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703‐1719.
Davis K, Sheikh T, Aggarwal N. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia. Semin Diagn Pathol. 2023;40(3):202‐215.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377.
Walter RB, Estey EH. Selection of initial therapy for newly‐diagnosed adult acute myeloid leukemia: limitations of predictive models. Blood Rev. 2020;44:100679.
Phelan KW, Advani AS. Novel therapies in acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2018;13(4):289‐299.
Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2023;98(3):502‐526.
Roskoski R Jr. The role of small molecule Flt3 receptor protein‐tyrosine kinase inhibitors in the treatment of Flt3‐positive acute myelogenous leukemias. Pharmacol Res. 2020;155:104725.
Bair SM, Brandstadter JD, Ayers EC, Stadtmauer EA. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer. 2020;126(9):1837‐1855.
Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645‐648.
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730‐737.
Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self‐renewal capacity. Nat Immunol. 2004;5(7):738‐743.
Valent P. Targeting of leukemia‐initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets. 2011;11(1):56‐71.
Taussig DC, Miraki‐Moud F, Anjos‐Afonso F, et al. Anti‐CD38 antibody‐mediated clearance of human repopulating cells masks the heterogeneity of leukemia‐initiating cells. Blood. 2008;112(3):568‐575.
Kong Y, Yoshida S, Saito Y, et al. CD34+CD38+CD19+ as well as CD34+CD38‐CD19+ cells are leukemia‐initiating cells with self‐renewal capacity in human B‐precursor ALL. Leukemia. 2008;22(6):1207‐1213.
Blatt K, Menzl I, Eisenwort G, et al. Phenotyping and target expression profiling of CD34+/CD38− and CD34+/CD38+ stem‐ and progenitor cells in acute lymphoblastic leukemia. Neoplasia. 2018;20(6):632‐642.
Herrmann H, Sadovnik I, Eisenwort G, et al. Delineation of target expression profiles in CD34+/CD38‐ and CD34+/CD38+ stem and progenitor cells in AML and CML. Blood Adv. 2020;4(20):5118‐5132.
Zhou J, Chng WJ. Identification and targeting leukemia stem cells: the path to the cure for acute myeloid leukemia. World J Stem Cells. 2014;6(4):473‐484.
Pabon CM, Abbas HA, Konopleva M. Acute myeloid leukemia: therapeutic targeting of stem cells. Expert Opin Ther Targets. 2022;26(6):547‐556.
Khaldoyanidi SK, Hindoyan A, Stein A, Subklewe M. Leukemic stem cells as a target for eliminating acute myeloid leukemia: gaps in translational research. Crit Rev Oncol Hematol. 2022;175:103710.
Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108(2):353‐366.
Agarwal P, Bhatia R. Influence of bone marrow microenvironment on leukemic stem cells: breaking up an intimate relationship. Adv Cancer Res. 2015;127:227‐252.
Valent P, Sadovnik I, Eisenwort G, et al. Immunotherapy‐based targeting and elimination of leukemic stem cells in AML and CML. Int J Mol Sci. 2019;20(17):4233.
Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524‐528.
Herrmann H, Blatt K, Shi J, et al. Small‐molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem‐ and progenitor cells in acute myeloid leukemia AML. Oncotarget. 2012;3(12):1588‐1599.
Follini E, Marchesini M, Roti G. Strategies to overcome resistance mechanisms in T‐cell acute lymphoblastic leukemia. Int J Mol Sci. 2019;20(12):3021.
Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c‐Myc and IL7R in high‐risk acute lymphoblastic leukemia. Blood. 2012;120(14):2843‐2852.
Roderick JE, Tesell J, Shultz LD, et al. c‐Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T‐ALL cells. Blood. 2014;123(7):1040‐1050.
Rathert P, Roth M, Neumann T, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015;525(7570):543‐547.
Fong CY, Gilan O, Lam EY, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525(7570):538‐542.
Winter GE, Buckley DL, Paulk J, et al. Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348(6241):1376‐1381.
Winter GE, Mayer A, Buckley DL, et al. BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol Cell. 2017;67(1):5‐18.e19.
Peter B, Eisenwort G, Sadovnik I, et al. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia. Am J Hematol. 2022;97(9):1215‐1225.
Zhang K, Gao L, Wang J, et al. A novel BRD family PROTAC inhibitor dBET1 exerts great anti‐cancer effects by targeting c‐MYC in acute myeloid leukemia cells. Pathol Oncol Res. 2022;28:1610447.
Piya S, Mu H, Bhattacharya S, et al. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. J Clin Invest. 2019;129(5):1878‐1894.
Short NJ, Konopleva M, Kadia TM, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506‐525.
van Gils N, Martiañez Canales T, Vermue E, et al. The novel oral BET‐CBP/p300 dual inhibitor NEO2734 is highly effective in eradicating acute myeloid leukemia blasts and stem/progenitor cells. Hema. 2021;5(8):e610.
Fedorov K, Maiti A, Konopleva M. Targeting FLT3 mutation in acute myeloid leukemia: current strategies and future directions. Cancers. 2023;15(8):2312.
Xia B, Tian C, Guo S, et al. c‐Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Leuk Res. 2015;39:92‐99.
Valent P, Bauer K, Sadovnik I, et al. Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: perspectives and open issues. Stem Cells Transl Med. 2020;9(11):1331‐1343.
Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20(3):158‐173.
Tabe Y, Konopleva M. Role of microenvironment in resistance to therapy in AML. Curr Hematol Malig Rep. 2015;10(2):96‐103.
Shafat MS, Gnaneswaran B, Bowles KM, Rushworth SA. The bone marrow microenvironment – home of the leukemic blasts. Blood Rev. 2017;31(5):277‐286.
Wang A, Zhong H. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia. Hematology. 2018;23(10):729‐739.
Ladikou EE, Sivaloganathan H, Pepper A, Chevassut T. Acute myeloid leukaemia in its niche: the bone marrow microenvironment in acute myeloid leukaemia. Curr Oncol Rep. 2020;22(3):27.
Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552‐1564.
Barrett AJ. Acute myeloid leukaemia and the immune system: implications for immunotherapy. Br J Haematol. 2020;188(1):147‐158.
Tsumura A, Levis D, Tuscano JM. Checkpoint inhibition in hematologic malignancies. Front Oncol. 2023;13:1288172.
Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra‐terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharmacol. 2021;11:621093.